Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 6/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407884 | 0.97 | HSD17B10 (0.51) | MAPTALDH1A1LMNAMAPK1HSD17B10 | |
| SCHEMBL29452862 | 0.81 | LMNA (0.78) | MAPTALDH1A1LMNAMAPK1HSD17B10 | |
| SCHEMBL1003250 | 0.81 | LMNA (0.78) | MAPTALDH1A1LMNAMAPK1HSD17B10 | |
| SCHEMBL31353091 | 0.80 | WNT3A (0.50) | MAPTALDH1A1LMNAMAPK1HSD17B10 | |
| SCHEMBL31353075 | 0.80 | WNT3A (0.50) | MAPTALDH1A1LMNAMAPK1HSD17B10 | |
| SCHEMBL6646157 | 0.80 | PARP1 (0.50) | ALDH1A1LMNAPARP1TNKS2TNK2 | |
| SCHEMBL25919036 | 0.80 | PARP1 (0.42) | HSD17B10PARP1MEN1KMT2AKCNH2 | |
| SCHEMBL6643842 | 0.80 | KDM4E (0.51) | ALDH1A1LMNAHSD17B10PARP1KCNH2 | |
| SCHEMBL6627508 | 0.79 | MAPT (0.75) | MAPTALDH1A1LMNAMAPK1HSD17B10 | |
| SCHEMBL6554641 | 0.78 | PARP1 (0.53) | PARP1KCNH2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-7067667-B2 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-27 | — | — | US | disclosed |
| EP-1129077-B9 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1129077-B1 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AG (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1054869-B1 | 3,4-DIHYDROQUINOLINE DERIVATIVES AS NITROGEN MONOXIDE SYNTHASE (NOS) INHIBITORS | SCHERING AG (DE) | 2004-09-22 | — | — | EP | disclosed |
| US-20040127712-A1 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | JAROCH STEFAN (DE) | 2004-07-01 | — | — | US | disclosed |
| EP-1115708-B1 | AMINOALKYL-3,4-DIHYDROQUINOLINE DERIVATES AS NO-SYNTHASE INHIBITORS | SCHERING AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-6579883-B1 | Nitrogen monoxide synthases; 4-amino-8-bromo-3a-fluoro-2,3,3a,9b-tetrahydro-1H-cyclopenta (c) quinoline; neurodegenerative, autoimmune, cardiovascular diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-17 | — | — | US | disclosed |
| US-6391887-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-05-21 | — | — | US | disclosed |
| EP-1129077-A1 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1054869-A1 | 3,4-DIHYDROQUINOLINE DERIVATIVES AS NITROGEN MONOXIDE SYNTHASE (NOS) INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000029381-A1 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-25 | — | — | WO | disclosed |
| WO-1999041240-A1 | 3,4-DIHYDROQUINOLINE DERIVATIVES AS NITROGEN MONOXIDE SYNTHASE (NOS) INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | MAPT 3390/4885ALDH1A1 1913/4885LMNA 316/4885 |
| US-20040127712-A1 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | NOS3, NOS1, NOS2 | MAPT 3021/4885ALDH1A1 260/4885LMNA 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.